Bradley Monk was named medical director of late-phase clinical research at Florida Cancer Specialists & Research Institute, LLC. Monks plans to leverage his experience and leadership across all tumor types as FCS expands in footprint in late-phase practice changing clinical trials.
A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow.
